1. Home
  2. NEXA vs ANAB Comparison

NEXA vs ANAB Comparison

Compare NEXA & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nexa Resources S.A.

NEXA

Nexa Resources S.A.

HOLD

Current Price

$10.83

Market Cap

1.6B

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$55.41

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXA
ANAB
Founded
1956
2005
Country
Luxembourg
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
NEXA
ANAB
Price
$10.83
$55.41
Analyst Decision
Hold
Strong Buy
Analyst Count
5
10
Target Price
$7.80
$66.70
AVG Volume (30 Days)
716.6K
442.1K
Earning Date
01-01-0001
05-25-2026
Dividend Yield
1.16%
N/A
EPS Growth
N/A
91.02
EPS
N/A
N/A
Revenue
N/A
$234,603,000.00
Revenue This Year
$6.99
N/A
Revenue Next Year
N/A
$43.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
157.01
52 Week Low
$4.62
$15.32
52 Week High
$14.94
$63.47

Technical Indicators

Market Signals
Indicator
NEXA
ANAB
Relative Strength Index (RSI) 42.67 54.46
Support Level $4.86 $43.67
Resistance Level $14.94 $57.70
Average True Range (ATR) 0.82 3.58
MACD -0.15 -0.02
Stochastic Oscillator 3.17 25.30

Price Performance

Historical Comparison
NEXA
ANAB

About NEXA Nexa Resources S.A.

Nexa Resources SA is a low-cost integrated zinc producer. It produces copper, silver, and gold as byproducts. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: